Press Releases

GlobeNewswire, Inc.

DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. Quarterly Highlights Net sales...

GlobeNewswire, Inc.

FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal...

GlobeNewswire, Inc.

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026....

GlobeNewswire, Inc.

MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NextNRG, Inc. (NASDAQ: NXXT) ("NextNRG" or the "Company"), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced financial results for the...

GlobeNewswire, Inc.

WILMINGTON, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the platform for agentic AI banking, will report financial results for its second quarter ended July 31, 2026, after the market close on Tuesday, August 25, 2026....

GlobeNewswire, Inc.

Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regeneration Continued favorable safety and tolerability profile, stable strength and improved...

GlobeNewswire, Inc.

GREENWICH, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Stardust Power Inc. (Nasdaq: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today announced the results for the quarter ended June 30, 2026...

GlobeNewswire, Inc.

Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the versatility of its RedTail platform at...

GlobeNewswire, Inc.

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models...

GlobeNewswire, Inc.

Revenues were up 20% year over year, reaching $1.1 million in the second quarter of 2026; gross margin was 51%, compared to 32% in the second quarter of 2025 New wins across Intelligent Transportation Systems (ITS), U.S. carriers, and...

GlobeNewswire, Inc.

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of...

GlobeNewswire, Inc.

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026 -- --...

GlobeNewswire, Inc.

Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to the Board of Directors -...

GlobeNewswire, Inc.

Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage declined 19% sequentially...

GlobeNewswire, Inc.

– Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash – – July monthly Zola® sales top $740K; exceed $1 million through first week of...

GlobeNewswire, Inc.

Net Asset Value ("NAV") of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted Cash, $65.2 million in Current Assets, and $2.4...

GlobeNewswire, Inc.

Summary: Matador generated gross proceeds of approximately $1.1 million under its ATM Program during the reporting period ended July 31, 2026, bringing aggregate gross proceeds since the program commenced to approximately $2.3 million.

GlobeNewswire, Inc.

TPV reached nearly US$18 billion (+92% year-over-year), the 7th consecutive quarter of 50%+ growth, and continued acceleration over the last 5 quarters.

GlobeNewswire, Inc.

$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted provider engagement,...

GlobeNewswire, Inc.

$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offering...